Progression of radiographic joint damage in rheumatoid arthritis: Independence of erosions and joint space narrowing

Annals of the Rheumatic Diseases

Volumn 68, Issue 10, 2009, Pages 1535-1540

  Smolen, J S ^a,b   Van Der Heijde, D M ^c   Aletaha, D ^a   Xu, S ^d   Han, J ^d   Baker, D ^d   St Clair, E W ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HIETZING HOSPITAL   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTOCOR INC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COURSE EVALUATION; DISEASE ACTIVITY; DRUG DOSE ESCALATION; HAND RADIOGRAPHY; HUMAN; IMAGE ANALYSIS; INTERPHALANGEAL JOINT; JOINT EROSION; JOINT RADIOGRAPHY; JOINT SPACE NARROWING; MAJOR CLINICAL STUDY; METACARPOPHALANGEAL JOINT; METATARSOPHALANGEAL JOINT; POST HOC ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FOOT JOINTS; HAND JOINTS; HUMANS; METHOTREXATE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 70349397415     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.094128     Document Type: Article

References (31)

1. Fex E, Jonsson K, Johnson U, et al. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996;35:1106-1115 (Pubitemid 126719646)
2. Sharp JT, Wolfe F, Mitchell DM, et al. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991;34:660-668
3. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
4. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-2792 (Pubitemid 44497757)
5. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44. (Pubitemid 43290588)
6. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies. J Rheumatol 1995;22:1974-1975
7. Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-720
8. Genant HK. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Semin Arthritis Rheum 2001;30:26-32.
9. van der Heijde DM. Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-453
10. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163 (Pubitemid 46245765)
11. Kitaura H, Zhou P, Kim HJ, et al. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-3427 (Pubitemid 43121830)
12. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-1488 (Pubitemid 32038586)
13. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-1699 (Pubitemid 33062512)
14. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-1427 (Pubitemid 35396913)
15. Pap T, Shigeyama Y, Kuchen S, et al. Differential expression pattern of membranetype matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000;43:1226-1232 (Pubitemid 30416307)
16. Rawdanowicz TJ, Hampton AL, Nagase H, et al. Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 1994;79:530-536 (Pubitemid 24983154)
17. Stephenson ML, Goldring MB, Birkhead JR, et al. Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin 1 beta or phorbol ester. Biochem Biophys Res Commun 1987;144:583-590
18. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-285 (Pubitemid 30060917)
19. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-792 (Pubitemid 34214261)
20. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-549 (Pubitemid 16049204)
21. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-266 (Pubitemid 29088117)
22. Strand V, Scott DL, Emery P, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601. (Pubitemid 40524689)
23. van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;333:1036-1038 (Pubitemid 19123055)
24. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
25. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443 (Pubitemid 39488667)
26. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681 (Pubitemid 38296553)
27. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602 (Pubitemid 32162982)
28. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001;60:817-827 (Pubitemid 32778171)
29. Bruynesteyn K, van der Heijde D, Boers M, et al. Contribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example. Arthritis Rheum 2002;47:532-536 (Pubitemid 35291376)
30. van der Heijde D, Landewe R, van Vollenhoven R, et al. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-1270
31. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-1030 (Pubitemid 40530107)